A Robust and Promising Pipeline

MedImmune's historical roots are in infectious disease. In 1998 we were the first company to launch a monoclonal antibody in the United States targeting an infectious disease. This product, Synagis^® (palivizumab), today produces more than $1 billion in revenues worldwide and more than 1 million doses have been distributed.

The company is also developing a vaccine to help prevent RSV, the most common cause of hospitalizations in children under one year of age, and is investigating whether antibodies can be used to treat infants hospitalized with this virus.

In 2008, MedImmune filed with the U.S. Food and Drug Administration for approval of an anti-RSV antibody, motavizumab.

MedImmune is driving innovation, having introduced in 2003 the first vaccine to use cutting-edge attenuated live virus technology (FluMist^®[Influenza Vaccine Live, Intranasal]). In 2007, we improved the formulation of FluMist^®, which significantly improved the storage and handling requirements for the vaccine. We also successfully expanded the label of the vaccine. We continually strive to seek ways to improve our technology and we're also exploring its role in helping prevent worldwide pandemics.

We are also exploring ways of bringing biologic technology to the most challenging infectious disease needs of our society. Research is ongoing in such diverse areas as herpes viruses, hepatitis C virus, antibacterials, and other respiratory viruses.

More than one in six people in developed countries are living with an immune-mediated inflammatory disease. The goal of MedImmune's Respiratory, Inflammation, and Autoimmunity (RIA) group is to develop innovative therapeutics to help improve the lives of these patients. Our strategic focus is currently on systemic lupus erythematosus (SLE), uncontrolled asthma, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis. We are also conducting exploratory work in a host of other related diseases. MedImmune's commitment to the RIA therapeutic area is designed to leverage industry-leading technology to deliver efficacious and convenient medicines for patients around the world.

According to estimates from the World Health Organization, in 2007, 11.3 million new cancer cases were diagnosed worldwide while 7.9 million people died from this disease. New cases of cancer are estimated to increase to 15.5 million in 2030. Risk of diagnosis and prognosis varies across different types of cancer, but significant progress remains to be made in addressing these diseases.

MedImmune's oncology product pipeline includes potential treatments for both solid tumor (breast, lung, etc.) and hematologic (lymphoma, leukemia, etc.) cancers. In addition, MedImmune's investigational biologic agents incorporate innovative technologies designed to eliminate cancer cells in more effective and targeted ways, such as effector enhanced, polyspecific, and toxin-carrying antibodies. MedImmune's discovery pipeline is focused on several key areas critical to the development and progression of cancer: vascular modulation, growth factor and survival signaling, and immune-mediated killing. Through innovative approaches, MedImmune's Oncology group strives to shift treatment paradigms to help extend and improve the lives of people with cancer.

At MedImmune, a wide range of opportunities in cardiovascular and gastrointestinal diseases are under investigation for improved treatment through biological approaches.

Our cardiovascular pipeline focuses on diseases including thrombosis and homeostasis, diabetes, and atherosclerotic disease. Treatments aimed at acute intervention in high-risk patients, as well as chronic treatment and long-term disease modification, have been identified as having potential for meeting unmet medical needs through specifically targeted biologics.

Chronic pain affects one in three people at some time in their lives, and is the number one cause of disability, carrying an immense socioeconomic burden. Current therapies have serious drawbacks in terms of efficacy, tolerability and responder rate, typically providing some relief in only one third to one half of the suffering population, according to the International Association for the Study of Pain. Similarly, according to the Alzheimer's Disease Society, every 17 seconds someone new develops Alzheimer's disease, and currently there are no therapies available which can affect the course of this devastating disease.

The goal of MedImmune's Neuroscience group is to discover and develop new therapies for the treatment of Alzheimer's disease, and for chronic inflammatory and neuropathic pain.